{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:26Z","timestamp":1790821946113,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,9,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ravulizumab provided rapid and sustained reduction in complement-mediated hemolysis at dosing intervals up to 12 weeks. Patients receiving higher trough exposures experienced greater frequency of LDH normalization, with no episodes of breakthrough hemolysis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018020644","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T11:54:21Z","timestamp":1535716461000},"page":"2176-2185","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":84,"title":["Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"first","affiliation":[{"name":"Department of Hematology, West German Cancer Center, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Rottinghaus","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Bachman","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, University of Ulm, Ulm, Germany;"},{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen\/University Hospital Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[{"name":"Clinical Immunology, Department of Internal Medicine, Centre Hospitalier R\u00e9gional Universitaire de Lille\u2013H\u00f4pital Claude Huriez, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[{"name":"Institute of Research Josep Carreras, Hospital Clinic Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Wells","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Haematology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Jang","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G.","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King's College Hospital, National Institute for Health Research and Wellcome King\u2019s Clinical Research Facility, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Aguzzi","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I.","family":"Damokosh","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Shafner","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-4166","authenticated-orcid":false,"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"2019111617090045700_B1","volume-title":"Soliris (eculizumab)","author":"US Food and Drug Administration","year":"2018"},{"key":"2019111617090045700_B2","volume-title":"Soliris (eculizumab)","author":"European Medicines Agency","year":"2017"},{"issue":"2","key":"2019111617090045700_B3","first-page":"205","article-title":"Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents","volume":"2","author":"Risitano","year":"2008","journal-title":"Biologics"},{"issue":"12","key":"2019111617090045700_B4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111617090045700_B5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111617090045700_B6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111617090045700_B7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"2019111617090045700_B8","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111617090045700_B9","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111617090045700_B10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria [published correction appears in Nat Biotechnol. 2007;25(12):1488]","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2019111617090045700_B11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1248\/bpb.b15-00703","article-title":"Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria","volume":"39","author":"Nakayama","year":"2016","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"2019111617090045700_B12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111617090045700_B13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12185-013-1346-4","article-title":"Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry","volume":"97","author":"Lee","year":"2013","journal-title":"Int J Hematol"},{"key":"2019111617090045700_B14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcmd.2017.03.013","article-title":"Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status","volume":"65","author":"Yenerel","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"25","key":"2019111617090045700_B15","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2019111617090045700_B16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111617090045700_B17","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes [published correction appears in Clin Ther. 2015;37(8):1870]","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"issue":"10","key":"2019111617090045700_B18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.imbio.2016.06.078","article-title":"Design and preclinical characterization of ALXN1210: a next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action [abstract]","volume":"221","author":"Sheridan","year":"2016","journal-title":"Immunobiology"},{"issue":"23","key":"2019111617090045700_B19","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood.V126.23.4777.4777","article-title":"First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals [abstract]","volume":"126","author":"Sahelijo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111617090045700_B20","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"issue":"22","key":"2019111617090045700_B21","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.V128.22.2428.2428","article-title":"Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH): interim analysis of a dose-escalation study [abstract]","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111617090045700_B22","first-page":"3482","article-title":"Optimization of dose regimen for ALXN1210, a novel complement C5 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH): results of 2 phase 1b\/2 studies [abstract]","volume":"130","author":"Roeth","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111617090045700_B23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2019111617090045700_B24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"2019111617090045700_B25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1445-5994.2012.02924.x","article-title":"Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria","volume":"43","author":"Weitz","year":"2013","journal-title":"Intern Med J"},{"issue":"5","key":"2019111617090045700_B26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111617090045700_B27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2019111617090045700_B28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"Int J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/17\/2176\/881559\/advances020644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/17\/2176\/881559\/advances020644.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:09:19Z","timestamp":1573924159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/17\/2176\/15847\/Ravulizumab-ALXN1210-in-patients-with-paroxysmal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,9,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018020644","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]}}}